Cargando…
Oral Mucositis Induced By Anticancer Therapies
Oral mucositis induced by conventional cytotoxic cancer therapies is a common and significant clinical problem in oncology. Mucositis symptoms, which include severe pain, may lead to dose reductions and unplanned interruptions of chemotherapy and/or radiotherapy, and often affect patients' qual...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4623065/ https://www.ncbi.nlm.nih.gov/pubmed/26523246 http://dx.doi.org/10.1007/s40496-015-0069-4 |
_version_ | 1782397635371466752 |
---|---|
author | Al-Ansari, Sali Zecha, Judith A. E. M. Barasch, Andrei de Lange, Jan Rozema, Fred R. Raber-Durlacher, Judith E. |
author_facet | Al-Ansari, Sali Zecha, Judith A. E. M. Barasch, Andrei de Lange, Jan Rozema, Fred R. Raber-Durlacher, Judith E. |
author_sort | Al-Ansari, Sali |
collection | PubMed |
description | Oral mucositis induced by conventional cytotoxic cancer therapies is a common and significant clinical problem in oncology. Mucositis symptoms, which include severe pain, may lead to dose reductions and unplanned interruptions of chemotherapy and/or radiotherapy, and often affect patients' quality of life. In addition, ulcerative mucositis represents a risk factor for local or systemic infectious complications that may be life-threatening in immunosuppressed patients. The development of biologically based targeted cancer therapies, which aim to block the growth, spread, and survival of tumors by interfering with specific molecular targets, may have reduced mucosal injury, but did not eliminate it. This article will review the epidemiology, pathobiology, and management of oral mucositis associated with conventional cytotoxic therapies for malignant diseases and will briefly summarize emerging information on oral mucosal injury associated with targeted therapies. Considerations for future research aimed at the development of more efficient and effective supportive care approaches will be presented, with emphasis on the contribution of dental researchers and clinicians in these efforts. |
format | Online Article Text |
id | pubmed-4623065 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-46230652015-10-30 Oral Mucositis Induced By Anticancer Therapies Al-Ansari, Sali Zecha, Judith A. E. M. Barasch, Andrei de Lange, Jan Rozema, Fred R. Raber-Durlacher, Judith E. Curr Oral Health Rep Epidemiology (M Laine, Section Editor) Oral mucositis induced by conventional cytotoxic cancer therapies is a common and significant clinical problem in oncology. Mucositis symptoms, which include severe pain, may lead to dose reductions and unplanned interruptions of chemotherapy and/or radiotherapy, and often affect patients' quality of life. In addition, ulcerative mucositis represents a risk factor for local or systemic infectious complications that may be life-threatening in immunosuppressed patients. The development of biologically based targeted cancer therapies, which aim to block the growth, spread, and survival of tumors by interfering with specific molecular targets, may have reduced mucosal injury, but did not eliminate it. This article will review the epidemiology, pathobiology, and management of oral mucositis associated with conventional cytotoxic therapies for malignant diseases and will briefly summarize emerging information on oral mucosal injury associated with targeted therapies. Considerations for future research aimed at the development of more efficient and effective supportive care approaches will be presented, with emphasis on the contribution of dental researchers and clinicians in these efforts. Springer International Publishing 2015-10-19 2015 /pmc/articles/PMC4623065/ /pubmed/26523246 http://dx.doi.org/10.1007/s40496-015-0069-4 Text en © The Author(s) 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Epidemiology (M Laine, Section Editor) Al-Ansari, Sali Zecha, Judith A. E. M. Barasch, Andrei de Lange, Jan Rozema, Fred R. Raber-Durlacher, Judith E. Oral Mucositis Induced By Anticancer Therapies |
title | Oral Mucositis Induced By Anticancer Therapies |
title_full | Oral Mucositis Induced By Anticancer Therapies |
title_fullStr | Oral Mucositis Induced By Anticancer Therapies |
title_full_unstemmed | Oral Mucositis Induced By Anticancer Therapies |
title_short | Oral Mucositis Induced By Anticancer Therapies |
title_sort | oral mucositis induced by anticancer therapies |
topic | Epidemiology (M Laine, Section Editor) |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4623065/ https://www.ncbi.nlm.nih.gov/pubmed/26523246 http://dx.doi.org/10.1007/s40496-015-0069-4 |
work_keys_str_mv | AT alansarisali oralmucositisinducedbyanticancertherapies AT zechajudithaem oralmucositisinducedbyanticancertherapies AT baraschandrei oralmucositisinducedbyanticancertherapies AT delangejan oralmucositisinducedbyanticancertherapies AT rozemafredr oralmucositisinducedbyanticancertherapies AT raberdurlacherjudithe oralmucositisinducedbyanticancertherapies |